Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9117916 | 0.82 | SLC40A1 (0.48) | SLC40A1POLBTDP1MEN1KMT2A | |
| SCHEMBL21962916 | 0.81 | CA1 (0.56) | SLC40A1POLBTDP1MEN1KMT2A | |
| SCHEMBL1466611 | 0.78 | TDP1 (0.51) | SLC40A1POLBTDP1MEN1KMT2A | |
| SCHEMBL29086564 | 0.77 | TDP1 (0.51) | SLC40A1POLBTDP1KMT2ACA1 | |
| SCHEMBL22010546 | 0.76 | MAP2K1 (0.41) | SLC40A1POLBTDP1MEN1KMT2A | |
| SCHEMBL22010548 | 0.76 | CA1 (0.45) | SLC40A1POLBTDP1CA1CA2 | |
| SCHEMBL8629880 | 0.76 | CA1 (0.57) | SLC40A1POLBTDP1KMT2ACA1 | |
| SCHEMBL3714382 | 0.76 | TDP1 (0.50) | SLC40A1POLBTDP1KMT2ACA1 | |
| Methyl Alcohol SCHEMBL27853401 | 0.76 | TDP1 (0.50) | SLC40A1POLBTDP1KMT2ACA1 | |
| SCHEMBL1466745 | 0.73 | SLC40A1 (0.56) | SLC40A1POLBTDP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3986879-B1 | FUSED 1,2-THIAZOLES AND 1,2-THIAZINES WHICH ACT AS NLRP3 MODULATORS | AC IMMUNE SA (CH) | 2024-10-02 | — | — | EP | disclosed |
| EP-3880666-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-06-28 | — | — | EP | disclosed |
| US-20230024859-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-01-26 | — | — | US | disclosed |
| US-20220378801-A1 | NOVEL COMPOUNDS | AC IMMUNE SA (CH) | 2022-12-01 | — | — | US | disclosed |
| EP-3986879-A1 | FUSED 1,2 THIAZOLES AND 1,2 THIAZINES WHICH ACT AS NL3P3 MODULATORS | AC Immune SA (CH) | 2022-04-27 | — | — | EP | disclosed |
| WO-2020102100-A9 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2022-01-06 | — | — | WO | disclosed |
| WO-2020254697-A1 | FUSED 1,2 THIAZOLES AND 1,2 THIAZINES WHICH ACT AS NL3P3 MODULATORS | AC IMMUNE SA (CH) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020254697-A1 | FUSED 1,2 THIAZOLES AND 1,2 THIAZINES WHICH ACT AS NL3P3 MODULATORS | AC IMMUNE SA (CH) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020102100-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230024859-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | SLC40A1 781/4885POLB 4622/4885TDP1 1513/4885 |
| US-20220378801-A1 | NOVEL COMPOUNDS | NLRP3, IL1B, IL18 | SLC40A1 2504/4885POLB 4184/4885TDP1 1887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.